Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7828301 | 0.92 | ALDH1A1 (0.47) | PTPRCMAPTSMN1; SMN2KMT2AHTT | |
| SCHEMBL7100834 | 0.74 | ALDH1A1 (0.45) | MAPTSMN1; SMN2KMT2AHTTF2 | |
| SCHEMBL7100881 | 0.73 | ALDH1A1 (0.41) | MAPTKMT2AHTTGAAF2 | |
| SCHEMBL7100452 | 0.73 | KMT2A (0.44) | MAPTSMN1; SMN2KMT2AHTTGAA | |
| SCHEMBL7667658 | 0.69 | ALDH1A1 (0.48) | METMAPTSMN1; SMN2HTTGAA | |
| SCHEMBL7100873 | 0.69 | MAPT (0.39) | MAPTKMT2AHTTGAAF2 | |
| SCHEMBL7100869 | 0.69 | MAPT (0.39) | MAPTKMT2AHTTGAAF2 | |
| SCHEMBL17687431 | 0.69 | PTPRC (0.63) | PTPRCMAPTSMN1; SMN2KMT2ANFE2L2 | |
| SCHEMBL13208612 | 0.69 | HTT (0.42) | MAPTSMN1; SMN2KMT2AHTTGAA | |
| 3-Nitrobenzaldehyde SCHEMBL7590570 | 0.68 | KMT2A (0.39) | MAPTSMN1; SMN2KMT2AHTTNFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ABBOTT LABORATORIES | 2003-04-17 | — | — | US | disclosed |
| US-6503935-B1 | Treating urinary incontinence or retrograde ejaculation | ABBOTT LABORATORIES | 2003-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ADRA1D, ADRB1, ADRA1A | PTPRC 4844/4885MET 4302/4885MAPT 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.